Streetbeat News

Price Targets

DOW

Barclays analyst Michael Leithead has maintained an Equal-Weight rating on Dow (NYSE:DOW) and increased the price target from $55 to $58, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 6:04 pm

CRWD

JMP Securities analyst Trevor Walsh has reaffirmed a Market Outperform rating on CrowdStrike Holdings (NASDAQ:CRWD) and increased the price target from $235 to $330.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 6:03 pm

MUR

Analysts have mixed views on Murphy Oil (NYSE:MUR), with recent ratings ranging from bullish to bearish. The average 12-month price target is $50.17, a slight decrease from the previous $51.20. Analysts from UBS, Piper Sandler, Keybanc, and Truist Securities have adjusted their ratings and price targets, reflecting changes in market dynamics and company performance. Murphy Oil, an independent oil and gas company, reported a revenue decline of -11.69% as of December 31, 2023, and faces challenges in profitability and asset utilization, with a net margin of 13.81%, ROE of 2.17%, and ROA of 1.18%. The company's debt-to-equity ratio is below the industry average at 0.39.

Portfolio Pulse from Benzinga Insights

January 29, 2024 | 6:00 pm

AXP

Analysts have recently updated their ratings and price targets for American Express (NYSE:AXP), with 11 analysts offering a range of opinions. The average 12-month price target is now $198.27, up from the previous $189.00. Analysts from firms like RBC Capital, UBS, and BMO Capital have raised their price targets, while others have announced new ratings. American Express has shown strong financial performance with a 13.57% revenue growth rate, a net margin of 15.76%, an ROE of 8.95%, an ROA of 0.98%, and a debt-to-equity ratio of 1.76.

Portfolio Pulse from Benzinga Insights

January 29, 2024 | 6:00 pm

AHCO

AdaptHealth (NASDAQ:AHCO) has received mixed analyst ratings over the past three months, with 2 bullish, 1 somewhat bullish, and 1 somewhat bearish. The average 12-month price target is now $9.88, down from $14.00, with a high estimate of $13.00 and a low of $6.50. Analysts from UBS, RBC Capital, B of A Securities, and Truist Securities have adjusted their price targets and ratings, reflecting changes in market conditions and company performance. AdaptHealth's financials show a market cap below industry benchmarks, a revenue growth of 4.67%, a net margin of -77.8%, an ROE of -23.21%, an ROA of -9.15%, and a debt-to-equity ratio of 1.33.

Portfolio Pulse from Benzinga Insights

January 29, 2024 | 6:00 pm

DKNG

MGM

PENN

Bank of America analyst Shaun C. Kelley maintains a Buy rating on DraftKings Inc (NASDAQ:DKNG) with a price target of $45, citing strong financials despite increased competition in the sports betting sector. Kelley raised revenue estimates for DraftKings for fiscal years 2024 and 2025 and anticipates a Q4 earnings beat and a possible guidance raise for 2024. DraftKings is expected to report Q4 earnings on Feb. 15, with analysts predicting an EPS of 9 cents and revenue of $1.241 billion. DraftKings shares have risen 1.64% to $39.10, with a 160% increase over the past year.

Portfolio Pulse from Chris Katje

January 29, 2024 | 5:53 pm

WAL

RBC Capital analyst Jon Arfstrom has maintained an Outperform rating on Western Alliance (NYSE:WAL) and increased the price target from $74 to $78.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 5:48 pm

REGN

RBC Capital analyst Brian Abrahams has reiterated an Outperform rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and maintained a price target of $1076.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 5:46 pm

OLN

RBC Capital analyst Arun Viswanathan has maintained an Outperform rating on Olin Corporation (NYSE:OLN) and increased the price target from $58 to $64, indicating a positive outlook on the stock.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 5:37 pm